相关临床试验
128
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
进行中（未招募）
1
0.8%
已完成
65
50.8%
Enrolling By Invitation
2
1.6%
尚未招募
5
3.9%
招募中
46
35.9%
终止
2
1.6%
Unknown
3
2.3%
撤回
4
3.1%
暂无批准数据
- Abu Dhabi Stem Cells Center has developed a breakthrough technique to generate brain stem cells from patients' own skin or blood cells, positioning the emirate among leading global research centers. - The virus-free reprogramming method converts patient cells into neural stem cells that could potentially treat neurological conditions including Parkinson's disease, Alzheimer's disease, and spinal cord injuries. - Using autologous cells reduces rejection risk and medication requirements, while researchers prepare to scale production and advance toward clinical applications. - The achievement strengthens Abu Dhabi's position in regenerative medicine alongside a separate partnership with Human Life CORD Japan to develop umbilical cord stem cell therapies.
- Post hoc analysis of the PhALLCON trial demonstrates that ponatinib achieved higher rates of deep molecular responses compared to imatinib in newly diagnosed Ph+ ALL patients who remained MRD-positive after induction therapy. - Patients with persistent MRD who continued ponatinib beyond cycle 3 showed significantly improved event-free survival with a median not reached versus 24.8 months for imatinib (HR 0.198, P = 0.0004). - The analysis supports continuing ponatinib treatment in Ph+ ALL patients who fail to achieve MRD negativity after initial induction, though researchers caution about the small patient numbers and potential selection bias.
